$POAI
Predictive Oncology Inc. Stock $poai

$poai Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000117184320005921 Filed on August 13, 2020

Income Statement

Concept	2020 Q2	2019 Q2
Revenue	$182.8K	$286.2K
YoY Change	-36.12%	-20.2%
Cost Of Revenue	$85.26K	$118.4K
YoY Change	-27.98%	8.64%
Gross Profit	$97.52K	$167.8K
YoY Change	-41.87%	-32.79%
Gross Profit Margin	53.35%	58.63%
Selling, General & Admin	$3.345M	$3.995M
YoY Change	-16.28%	211.26%
% of Gross Profit	3429.79%	2381.6%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$119.0K	$131.4K
YoY Change	-9.47%	598.11%
% of Gross Profit	122.0%	78.34%
Operating Expenses	$3.345M	$3.995M
YoY Change	-16.28%	211.26%
Operating Profit	-$3.768M	-$5.099M
YoY Change	-26.09%	260.88%
Interest Expense	$870.0K	$6.160M
YoY Change	-85.88%	-741.67%
% of Operating Profit
Other Income/Expense, Net	-$680.0K	-$819.3K
YoY Change	-17.0%
Pretax Income	-$3.580M	$1.470M
YoY Change	-343.54%	-162.03%
Income Tax
% Of Pretax Income
Net Earnings	-$3.577M	$1.465M
YoY Change	-344.17%	-161.73%
Net Earnings / Revenue	-1957.16%	512.0%
Basic Earnings Per Share	-$0.36	$0.49
Diluted Earnings Per Share	-$0.36	$0.24
COMMON SHARES
Basic Shares Outstanding	9.838M	2.961M
Diluted Shares Outstanding	9.838M	6.007M

Balance Sheet

Concept	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.390M	$70.00K
YoY Change	4742.86%	-93.0%
Cash & Equivalents	$3.394M	$69.56K
Short-Term Investments
Other Short-Term Assets	$430.0K	$150.0K
YoY Change	186.67%	-46.43%
Inventory	$235.4K	$320.9K
Prepaid Expenses
Receivables	$272.5K	$299.0K
Other Receivables	$0.00	$250.0K
Total Short-Term Assets	$4.329M	$1.094M
YoY Change	295.67%	-45.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.410M	$1.770M
YoY Change	36.16%	859.85%
Goodwill	$15.69M	$23.79M
YoY Change	-34.05%
Intangibles	$3.540M	$4.592M
YoY Change	-22.92%	3888.11%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$23.17M	$31.16M
YoY Change	-25.64%	1462.73%
TOTAL ASSETS
Total Short-Term Assets	$4.329M	$1.094M
Total Long-Term Assets	$23.17M	$31.16M
Total Assets	$27.50M	$32.25M
YoY Change	-14.74%	706.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.449M	$3.539M
YoY Change	-30.8%	2037.13%
Accrued Expenses	$2.649M	$1.036M
YoY Change	155.83%	127.42%
Deferred Revenue	$38.58K	$29.71K
YoY Change	29.88%	61.96%
Short-Term Debt	$0.00	$3.810M
YoY Change	-100.0%
Long-Term Debt Due	$5.467M
YoY Change
Total Short-Term Liabilities	$14.65M	$9.456M
YoY Change	54.95%	1377.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$98.36K	$500.0K
YoY Change	-80.33%
Total Long-Term Liabilities	$98.36K	$500.0K
YoY Change	-80.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.65M	$9.456M
Total Long-Term Liabilities	$98.36K	$500.0K
Total Liabilities	$15.81M	$9.960M
YoY Change	58.69%	1458.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$90.61M	-$64.94M
YoY Change	39.53%	10.25%
Common Stock	$131.9K	$309.7K
YoY Change	-57.41%	156.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.69M	$22.29M
YoY Change
Total Liabilities & Shareholders Equity	$27.50M	$32.25M
YoY Change	-14.74%	706.08%

Cashflow Statement

Concept	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$3.577M	$1.465M
YoY Change	-344.17%	-161.73%
Depreciation, Depletion And Amortization	$119.0K	$131.4K
YoY Change	-9.47%	598.11%
Cash From Operating Activities	-$3.750M	-$2.000M
YoY Change	87.5%	40.85%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$10.00K
YoY Change	0.0%	-90.0%
Acquisitions
YoY Change
Other Investing Activities	$130.0K	$50.00K
YoY Change	160.0%
Cash From Investing Activities	$120.0K	$40.00K
YoY Change	200.0%	-136.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.960M	890.0K
YoY Change	344.94%	217.86%
NET CHANGE
Cash From Operating Activities	-3.750M	-2.000M
Cash From Investing Activities	120.0K	40.00K
Cash From Financing Activities	3.960M	890.0K
Net Change In Cash	330.0K	-1.070M
YoY Change	-130.84%	-14.4%
FREE CASH FLOW
Cash From Operating Activities	-$3.750M	-$2.000M
Capital Expenditures	-$10.00K	-$10.00K
Free Cash Flow	-$3.740M	-$1.990M
YoY Change	87.94%	50.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	poai	Extinguishment Of Convertible Debt ExtinguishmentOfConvertibleDebt
	poai	Extinguishment Of Convertible Debt ExtinguishmentOfConvertibleDebt	220241
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Registrant Name EntityRegistrantName	Predictive Oncology Inc.
	poai	Consideration For Extinguishment Of Debt ConsiderationForExtinguishmentOfDebt
	poai	Consideration For Extinguishment Of Debt ConsiderationForExtinguishmentOfDebt	26711191
	poai	Derivatives Debt Issued DerivativesDebtIssued	141463
	poai	Derivatives Debt Issued DerivativesDebtIssued
	poai	Equity Instruments Issued Conversion Of Convertible Debt EquityInstrumentsIssuedConversionOfConvertibleDebt	-20695
	poai	Equity Instruments Issued Conversion Of Convertible Debt EquityInstrumentsIssuedConversionOfConvertibleDebt
	poai	Equity Instruments Issued For Management And Consulting EquityInstrumentsIssuedForManagementAndConsulting	397300
	poai	Equity Instruments Issued For Management And Consulting EquityInstrumentsIssuedForManagementAndConsulting
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001446159
	dei	Document Type DocumentType	10-Q
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Trading Symbol TradingSymbol	poai
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15213188
	poai	Forebearanace Settlement On Bridge Loan ForebearanaceSettlementOnBridgeLoan
	poai	Forebearanace Settlement On Bridge Loan ForebearanaceSettlementOnBridgeLoan	503009
	poai	Gain Loss On Receivable Previously Considered Uncollectable GainLossOnReceivablePreviouslyConsideredUncollectable	1290000
CY2020Q2	poai	Finitelived Intangible Asset Expected Amortization After Year Four FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour	2162608
	poai	Gain Loss On Receivable Previously Considered Uncollectable GainLossOnReceivablePreviouslyConsideredUncollectable
CY2020Q2	poai	Gain Loss On Receivable Previously Considered Uncollectable GainLossOnReceivablePreviouslyConsideredUncollectable	1290000
CY2019Q2	poai	Gain Loss On Receivable Previously Considered Uncollectable GainLossOnReceivablePreviouslyConsideredUncollectable
	poai	Gain Loss On Revaluation Of Equity Method Investment GainLossOnRevaluationOfEquityMethodInvestment
	poai	Gain Loss On Revaluation Of Equity Method Investment GainLossOnRevaluationOfEquityMethodInvestment	6164260
CY2020Q2	poai	Gain Loss On Revaluation Of Equity Method Investment GainLossOnRevaluationOfEquityMethodInvestment
CY2019Q2	poai	Gain Loss On Revaluation Of Equity Method Investment GainLossOnRevaluationOfEquityMethodInvestment	6164260
	poai	Gain Losses On Debt Revaluation GainLossesOnDebtRevaluation
	poai	Gain Losses On Debt Revaluation GainLossesOnDebtRevaluation	1222244
CY2020Q2	poai	Gain Losses On Debt Revaluation GainLossesOnDebtRevaluation
CY2019Q2	poai	Gain Losses On Debt Revaluation GainLossesOnDebtRevaluation	1222244
	poai	Increase In Operating Lease Right Of Asset And Lease Liability Due To Lease Modification IncreaseInOperatingLeaseRightOfAssetAndLeaseLiabilityDueToLeaseModification	995571
	poai	Increase In Operating Lease Right Of Asset And Lease Liability Due To Lease Modification IncreaseInOperatingLeaseRightOfAssetAndLeaseLiabilityDueToLeaseModification
	poai	Inducement Shares Issued For Debt Extension InducementSharesIssuedForDebtExtension	41250
	poai	Inducement Shares Issued For Debt Extension InducementSharesIssuedForDebtExtension
CY2020Q1	poai	Issuance Of Shares And Prefunded Warrants Pursuant To Private Placement Value IssuanceOfSharesAndPrefundedWarrantsPursuantToPrivatePlacementValue	457823
	poai	Payments For Penalties PaymentsForPenalties	247327
	poai	Payments For Penalties PaymentsForPenalties
	poai	Proceeds From Debt And Equity Financing Net ProceedsFromDebtAndEquityFinancingNet	9874355
	poai	Proceeds From Issuance Of Stock Pursuant To Equity Line ProceedsFromIssuanceOfStockPursuantToEquityLine	1869899
	poai	Proceeds From Issuance Of Stock Pursuant To Equity Line ProceedsFromIssuanceOfStockPursuantToEquityLine
	poai	Stock And Notes Issued StockAndNotesIssued	1492500
	poai	Stock And Notes Issued StockAndNotesIssued
	poai	Stock Issued During Period Shares Exchange Agreement StockIssuedDuringPeriodSharesExchangeAgreement	2322878
	poai	Stock Issued During Period Shares Exchange Agreement StockIssuedDuringPeriodSharesExchangeAgreement
CY2019Q2	poai	Stock Issued During Period Value Convertible Preferred Shares Issued StockIssuedDuringPeriodValueConvertiblePreferredSharesIssued	743560
CY2019Q2	poai	Stock Issued During Period Value Extinguishment Of Debt StockIssuedDuringPeriodValueExtinguishmentOfDebt	6463309
CY2019Q1	poai	Stock Issued During Period Value Forebearance For Bridge Loan StockIssuedDuringPeriodValueForebearanceForBridgeLoan	158349
CY2020Q1	poai	Stock Issued During Period Value Inducement To Convertible Debt StockIssuedDuringPeriodValueInducementToConvertibleDebt	120000
CY2020Q1	poai	Stock Issued During Period Value Inducement To Equity Line StockIssuedDuringPeriodValueInducementToEquityLine	1869899
CY2020Q1	poai	Stock Issued During Period Value Inducement To Promissory Note Extension StockIssuedDuringPeriodValueInducementToPromissoryNoteExtension	41250
CY2020Q2	poai	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1694985
CY2019Q2	poai	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	5786
	poai	Waiver Shares Issued For Convertible Debt WaiverSharesIssuedForConvertibleDebt	99305
	poai	Waiver Shares Issued For Convertible Debt WaiverSharesIssuedForConvertibleDebt
	poai	Warrants Issued WarrantsIssued
	poai	Warrants Issued WarrantsIssued	32215
	poai	Warrants Issued Debt Issuance WarrantsIssuedDebtIssuance	179324
	poai	Warrants Issued Debt Issuance WarrantsIssuedDebtIssuance
	poai	Weighted Average Number Of Shares Abeyance Shares WeightedAverageNumberOfSharesAbeyanceShares	122000
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2449046
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3155641
CY2020Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	272493
CY2019Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	297055
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	272493
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	297055
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2649160
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2371633
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	879423
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	771574
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102163864
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93653667
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	287838
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	134939
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	263600
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1380620
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	116951
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	62373
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	6261591
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	134939
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1380620
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	422777
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1644220
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	858353
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1068256
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	153689
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	106060
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	77184
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	88416
CY2020Q2	us-gaap	Assets Assets	27496401
CY2019Q4	us-gaap	Assets Assets	22375510
CY2020Q2	us-gaap	Assets Current AssetsCurrent	4328643
CY2019Q4	us-gaap	Assets Current AssetsCurrent	798264
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	248102
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3394078
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150831
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	150831
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	162152
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3394078
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	69557
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3243247
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-92595
CY2020Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2020Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2818144
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	2814798
CY2020Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	4629570
CY2020Q2	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	50989
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13190787
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4056652
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	131908
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	40567
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Credit Risk </div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any <div style="display: inline; font-style: italic; font: inherit;">one</div> financial institution. The Company has a credit risk of <div style="display: inline; font-style: italic; font: inherit;">$2,818,144</div> for cash amounts held in a single institution that are in excess of amounts issued by the Federal Deposit Insurance Corporation.</div></div></div></div></div></div></div></div></div>
CY2020Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	38582
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	40384
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	38582
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	40384
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	35000
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	85261
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	118390
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	177918
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	192106
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	267328
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	238573
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	4694476
CY2019Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5146226
CY2020Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	282099
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	350426
CY2020Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	282099
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	350426
	us-gaap	Depreciation Depreciation	249049
	us-gaap	Depreciation Depreciation	153302
CY2020Q2	us-gaap	Depreciation Depreciation	118974
CY2019Q2	us-gaap	Depreciation Depreciation	131420
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	402738
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	259362
CY2020Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4629570
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	50989
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.49
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2019Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	50989
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-231347
CY2020Q2	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	1701756
CY2019Q2	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-211939
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	50989
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3310368
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6040293
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4808314
CY2020Q2	us-gaap	Goodwill Goodwill	15690290
CY2019Q4	us-gaap	Goodwill Goodwill	15690290
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-394974
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-231348
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-118472
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-300000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3211817
CY2019Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	59210
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	394974
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	231348
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	27107
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	422081
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	568300
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	414611
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	308201
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	154101
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	159868
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	159868
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	196951
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3141597
CY2020Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-422081
CY2019Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-211940
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-66989
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	197182
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8100000
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020Q2	us-gaap	Gross Profit GrossProfit	97523
CY2019Q2	us-gaap	Gross Profit GrossProfit	167761
	us-gaap	Gross Profit GrossProfit	299809
	us-gaap	Gross Profit GrossProfit	349286
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-439637
CY2020Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments
CY2019Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-614651
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	718483
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-113769
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-141325
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	505380
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-104114
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1802
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	6641
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	45212
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	55665
	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent
	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	975000
CY2020Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	4107897
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	4064023
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3539597
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3649412
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	42746
CY2020Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	69407
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	91410
CY2020Q2	us-gaap	Inventory Net InventoryNet	235368
CY2019Q4	us-gaap	Inventory Net InventoryNet	190156
CY2020Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	154794
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	69821
CY2020Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11167
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	28925
CY2020Q2	us-gaap	Liabilities Liabilities	15805243
CY2019Q4	us-gaap	Liabilities Liabilities	11144192
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27496401
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22375510
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	14651778
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10873928
CY2020Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2020Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	5466830
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9874355
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4533813
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	89976
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-580913
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6721084
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4045495
	us-gaap	Net Income Loss NetIncomeLoss	-8106695
	us-gaap	Net Income Loss NetIncomeLoss	-1828080
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-3577378
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	1465104
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4529317
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3293184
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3577378
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1444706
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8106695
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1848478
CY2020Q2	us-gaap	Notes Payable NotesPayable	4412377
CY2019Q4	us-gaap	Notes Payable NotesPayable	4795800
CY2020Q2	us-gaap	Notes Payable Current NotesPayableCurrent	4412377
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4795800
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
	us-gaap	Open Tax Year OpenTaxYear	2016 2017 2018 2019 2020
CY2020Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	521116
CY2019Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1271258
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1069869
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1737824
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3768425
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5098894
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7207777
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7436097
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	473043
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	459481
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1055107
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	270264
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1528150
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	729745
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	98358
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent
CY2020Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	729837
CY2019Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	607343
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1846912
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1157711
CY2020Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	52965
CY2019Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-3223
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	52968
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	50209
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	43874
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8433
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	426704
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	160222
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 0; font-size: 10pt"><div style="display: inline; font-weight: bold;">Reclassifications</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">Certain reclassifications have been made to the prior years' financial statements to conform to the current year presentation. The reclassifications had <div style="display: inline; font-style: italic; font: inherit;">no</div> effect on previously reported results of operations, cash flows or accumulated deficit.</div></div></div></div></div></div></div></div></div>
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5057919
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2479708
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	743560
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2761867
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1525000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	25416
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities
	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable
	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	154418
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	133850
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1866554
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5786
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3289144
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2279373
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2409721
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1507799
	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses
	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	795353
	us-gaap	Repayments Of Debt RepaymentsOfDebt	1459973
	us-gaap	Repayments Of Debt RepaymentsOfDebt
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90605406
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-82498711
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	182784
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	286151
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	477727
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	541392
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	133015
CY2019Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	685029
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	397424
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1239245
	us-gaap	Share Based Compensation ShareBasedCompensation	422777
	us-gaap	Share Based Compensation ShareBasedCompensation	1644220
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2020Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	362300
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	130000
CY2020Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2192878
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11231318
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	10355390
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2019Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5612250
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	11691158
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	53472
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	70005
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	22291588
CY2020Q2	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment
CY2019Q2	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	20398
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	20398
CY2020Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Accounting Policies and Estimates</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements during the reporting period. Actual results could materially differ from those estimates.</div></div></div></div></div></div></div></div></div>
CY2020Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2019Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3046141
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9838152
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6007078
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7362240
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2274754
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9838152
CY2019Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2960937
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7362240
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2274754

Files In Submission

Name	View Source	Status
0001171843-20-005921-index-headers.html	Edgar Link	pending
0001171843-20-005921-index.html	Edgar Link	pending
0001171843-20-005921.txt	Edgar Link	pending
0001171843-20-005921-xbrl.zip	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
f10q_081320p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
poai-20200630.xml	Edgar Link	completed
poai-20200630.xsd	Edgar Link	pending
poai-20200630_cal.xml	Edgar Link	unprocessable
poai-20200630_def.xml	Edgar Link	unprocessable
poai-20200630_lab.xml	Edgar Link	unprocessable
poai-20200630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$POAI
Predictive Oncology Inc. Stock $poai

2020 Q2 Form 10-Q Financial Statement

#000117184320005921 Filed on August 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$POAI Predictive Oncology Inc. Stock $poai

2020 Q2 Form 10-Q Financial Statement

#000117184320005921 Filed on August 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$POAI
Predictive Oncology Inc. Stock $poai